We are live on ! Find out more
MBX

MBX Biosciences
MBX

157 hedge funds and large institutions have $1.57B invested in MBX Biosciences in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 43 increasing their positions, 47 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more call options, than puts

Call options by funds: $3.68M | Put options by funds: $1.46M

117% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 18

14% more funds holding

Funds holding: 138 → 157 (+19)

2.72% more ownership

Funds ownership: 107.85% → 110.58% (+2.7%)

3% more capital invested

Capital invested by funds: $1.53B → $1.57B (+$40.7M)

9% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 47

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

Holders
157
Holders Change
+19
Holders Change %
+13.77%
% of All Funds
1.93%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.07%
New
39
Increased
43
Reduced
47
Closed
18
Calls
$3.68M
Puts
$1.46M
Net Calls
+$2.22M
Net Calls Change
+$12.1M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$99.3M
2
PCH
Polar Capital Holdings
United Kingdom
+$55.2M
3
AWA
Aaron Wealth Advisors
Illinois
+$37.3M
4
CP
Caligan Partners
New York
+$28.9M
5
B
Braidwell
Connecticut
+$16.1M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$45.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$21.5M
3
DTC
Deep Track Capital
Connecticut
-$16.7M
4
DCM
Driehaus Capital Management
Illinois
-$13.3M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$16.8M +$3.48M +102,366 +22%
SC
27
Stempoint Capital
New York
$14.9M +$14.3M +420,916 +536%
Goldman Sachs
28
Goldman Sachs
New York
$13.7M +$4.29M +126,007 +38%
UBS Group
29
UBS Group
Switzerland
$10.4M +$2.23M +65,702 +23%
CS
30
Candriam SCA
Luxembourg
$8.79M +$10M +294,374 New
VPM
31
Vanguard Portfolio Management
Pennsylvania
$8.75M +$9.97M +293,295 New
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$8.62M -$13M -382,949 -57%
RSCM
33
Rock Springs Capital Management
Maryland
$8.6M +$182K +5,343 +2%
OM
34
Opaleye Management
Massachusetts
$7.76M – – –
Charles Schwab
35
Charles Schwab
California
$6.42M -$247K -7,272 -3%
EC
36
Elmind Capital
New York
$6.3M – – –
Northern Trust
37
Northern Trust
Illinois
$6.29M +$670K +19,694 +10%
BFM
38
Boothbay Fund Management
New York
$6.21M +$7.08M +208,049 New
SCM
39
Soleus Capital Management
Connecticut
$5.34M -$7.82M -230,003 -56%
DCM
40
DAFNA Capital Management
California
$5.24M +$347K +10,200 +6%
VFT
41
Vanguard Fiduciary Trust
Pennsylvania
$5.08M +$5.79M +170,154 New
GIM
42
Goelzer Investment Management
Indiana
$4.9M -$1.96M -57,500 -26%
AAA
43
Affinity Asset Advisors
New York
$4.48M -$3.4M -100,000 -40%
TAM
44
TFG Asset Management
Cayman Islands
$4.34M +$73.2K +2,153 +2%
JP Morgan Chase
45
JP Morgan Chase
New York
$3.96M +$4.5M +132,412 +904%
SSA
46
Schonfeld Strategic Advisors
New York
$3.7M -$1.47M -43,311 -26%
KCA
47
KVP Capital Advisors
California
$3.63M – – –
TD Asset Management
48
TD Asset Management
Ontario, Canada
$3.46M +$495K +14,548 +14%
Two Sigma Investments
49
Two Sigma Investments
New York
$3.43M -$799K -23,496 -17%
BGM
50
Burkehill Global Management
New York
$2.98M – – –
1
2
3 4 5

MBX Hedge Fund Activity: Q1 2026 in Review

157 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q1 2026, worth a combined $1.57B — up 2.7% from $1.53B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new MBX positions and 18 closed out — a net gain of 21 holders — while 43 added to existing stakes and 47 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $99.3M. The largest seller was EcoR1 Capital, cutting an estimated $45.8M.

  • 157 institutional investors held MBX Biosciences (MBX) as of Q1 2026, up from 138 in Q4 2025.
  • Funds reported $1.57B of MBX Biosciences stock for Q1 2026, up 2.7% quarter-over-quarter.
  • 39 funds opened new MBX Biosciences positions in Q1 2026 and 18 closed out, a net change of +21 holders.
  • The largest MBX Biosciences buyer in Q1 2026 was Fidelity Investments, an estimated $99.3M added.
  • The largest MBX Biosciences seller in Q1 2026 was EcoR1 Capital, an estimated $45.8M sold.

Based on aggregated 13F filings for Q1 2026.